Showing results (1721-1730 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|July 8, 2018
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumorsMichael Carducci, Montaser Shaheen, Ben Markman, et al.Investigational New Drugs|August 2, 2018
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinibFrancesco Facchinetti, Letizia Gnetti, Valeria Balestra, et al.Investigational New Drugs|December 28, 2005
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanomaKarl D Lewis, John A Thompson, Jeffrey S Weber, et al.Investigational New Drugs|December 28, 2005
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomasH W M van Laarhoven, G Gambarota, A Heerschap, et al.Investigational New Drugs|October 14, 2009
Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myelomaJae-Cheol Jo, Byung Woog Kang, Sun Jin Sym, et al.Investigational New Drugs|January 1, 1997
Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancerE K Rowinsky, W A Flood, S E Sartorius, et al.Investigational New Drugs|August 11, 1992
Phase II study of didemnin B in advanced colorectal cancerD V Jones, J A Ajani, R Blackburn, et al.Investigational New Drugs|September 9, 2018
CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemiaMuhammed H Rahaman, Yingyi Yu, Longjin Zhong, et al.Investigational New Drugs|September 11, 2018
Novel N-1 substituted fluoroquinolones inhibit human topoisomerase I activity and exhibit anti-proliferative activityLisa M Oppegard, Justine L Delgado, Chaitanya A Kulkarni, et al.Pageof 372